Dr. Lori Payton brings more than 25 years of broad experience leading strategic planning, clinical development and operational management in the biopharmaceutical industry. In her role at AlloVir, Dr. Payton leads multiple functions that support clinical development of the company's pipeline including, clinical operations, outsourcing & contracts, program management, and clinical quality & compliance. Dr. Payton also works with the Senior Management team to drive performance and execution in alignment with current and future development strategies.
Dr. Payton started her career at Pfizer, where she held various roles spanning the entire drug development continuum and led the teams accountable for the registration and commercialization of several medicines, including the blockbuster treatments Celebrex and Eliquis. Dr. Payton has advanced new therapies across a wide range of therapeutic areas from preclinical stages through commercialization. Most recently, Dr. Payton served as Senior Vice President, Strategy, Portfolio and Program Management at Sage Therapeutics where she led generation of the R&D strategy and portfolio planning process that informed investment in the Sage pipeline and established the operating model for the growing organization. In a prior role, Dr. Payton was Vice President and Global Medicine Team Leader at Alexion Pharmaceuticals, where she led a multi-indication team through strategic planning and execution to achieve global registrations for a new therapy to treat compliment-mediated rare diseases with industry leading timing.
Dr. Payton received her PhD in Pharmacology and Experimental Medicine from Boston University School of Medicine and BA from Wheaton College.